Pandemic did not interrupt HIV treatment during trials assessing long-acting ART

Study results presented at IDWeek demonstrated that the pandemic did not cause HIV treatment interruptions during the numerous global trials assessing long-acting cabotegravir and rilpivirine for ART. “We know that COVID-19 has caused health care system disruptions globally,” Maggie Czarnogorski, MD, MPH, head of innovation and implementation science at ViiV Healthcare, told Healio.

Read the full article here

Related Articles